What is HC Wainwright's Estimate for JSPR Q1 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($1.48) per share for the quarter. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics' Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

Several other brokerages also recently commented on JSPR. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $63.00 target price on the stock. JMP Securities reissued a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research report on Thursday. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $67.75.

Jasper Therapeutics Trading Down 5.1 %

Shares of NASDAQ:JSPR traded down $0.36 during trading on Monday, hitting $6.69. 1,119,480 shares of the company's stock traded hands, compared to its average volume of 1,725,909. The company has a 50-day moving average price of $21.09 and a 200-day moving average price of $20.15. Jasper Therapeutics has a 52 week low of $6.30 and a 52 week high of $31.01. The company has a market cap of $100.36 million, a price-to-earnings ratio of -1.41 and a beta of 2.18.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets grew its holdings in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after acquiring an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics during the third quarter worth about $59,000. MetLife Investment Management LLC boosted its position in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $251,000. Finally, Rhumbline Advisers acquired a new position in shares of Jasper Therapeutics during the 2nd quarter worth approximately $300,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.